Background: Praneem, a candidate vaginal microbicide with reported anti-HIV and contraceptive properties was evaluated for its long-term safety through a double-blind, placebo controlled, randomized Phase II trial.
Study design and randomization:
This was a double-blind, placebo controlled, randomized Phase II trial. The accrual of sample size of 100 was targeted with equal allocation in the Praneem or the placebo groups. Subjects were randomly allocated in equal proportion to the two study arms (50 subjects to the Praneem arm and 50 to the Placebo arm). Prior to the start of the study, the Data Management Center (DMC) at NARI prepared a random allocation list using the table of random permuted blocks. The random allocation list was kept under safe custody at the DMC and was not accessible to study investigators.
The Praneem / placebo tablets packed in identical strips by the manufacturer were received by the DMC. Necessary product related information was also provided on the label of each strip. The DMC prepared individual boxes containing either Praneem / placebo as per the random allocation. Stock sufficient for at least 6 months was packed in each box. These boxes were labeled with identification numbers 1 to 100 marked. The boxes were sent to the study sites and were stored under lock and key.
After confirming eligibility for enrollment, consecutive participants were given enrollment numbers from 1 to 100 in the sequential order. They were dispensed with two strips of the product from the box numbered with their corresponding enrollment number at the enrollment visit. During the monthly follow-up visits they were issued with one or two strips of the product depending upon their usage during the previous month. The clinic team coordinated with the DMC and ensured that these boxes contained sufficient stock to be issued to the participants when they come for follow up visits. On completion of the study, de-coding was done under the supervision of an independent group of two external experts and then product codes were incorporated into the study database for analysis.
Data analysis was done using SPSS 10.0 version for windows. Descriptive statistical analysis was performed for baseline characteristics. Chi-square test / Fisher's exact test was used for assessing statistical significance for the difference between the praneem and placebo groups. Person months of follow up were calculated for each participant. Incidence and 95% confidence intervals were calculated for various adverse events.
Screening procedures:
The study inclusion criteria for screening were women between 18 and 45 years of age, HIV-negative by licensed EIA, having a single male sexual partner, having a regular menstrual cycle with a minimum of 21 days between menses, not having any Grade III or higher hematological, liver and renal abnormality, having a normal Pap smear at screening, not planning to become pregnant in the subsequent two years and willing to use the study product only as per the protocol. Participants who were pregnant or lactating and those with any clinical or laboratory evidence of a sexually transmitted infections were excluded from the study.
Women were screened for their eligibility after signing the written informed consents. Other procedures included pelvic examination, cervical cytology, vaginal pH test and wet mount (to assess for the presence of trichomoniasis, candidiasis or bacterial vaginosis). Specimens for cervical cytology were stained by Papanicolaou stains and were evaluated for any abnormality using the revised Bethesda system 13 . Additional cervical specimens were collected for gram stain for gram negative intracellular diplococci and culture for gonorrhoea on modified Thayer-Martin medium (HiMedia, Mumbai, India). Cervical specimens could not be tested at screening for Chlamydia infection due to lack of infrastructure at that time however a through clinical and pelvic examination was done to rule out symptomatic participants with cervical discharge. Blood samples were tested for HIV antibody test by using enzyme-linked immunosorbent assay (Labsystems, Finland and Tridot, J. Mitra Co.), Rapid plasma reagin test with confirmation by Treponema pallidum haemagglutination (TPHA) test, complete blood count and biochemistry. Treatment for STIs was provided based on the WHO guidelines 14 . Potentially eligible participants were called for an enrollment visit approximately 10 days after and within 30 days of their screening date. Between screening and enrollment, male partners were provided information about the study and were also consented for the study. Final eligibility was assessed on the day of enrollment based on the screening test results and pelvic examination and colposcopy according to the CONRAD/WHO Manual for the Standardization of Colposcopy for the Evaluation of Vaginal Products, Update 2000 15 . Pelvic examination procedures at the enrollment visit were similar to the screening procedures except for collection of Pap smear.
Study procedures:
Participants were instructed to insert one tablet intra-vaginally using fingers at least half an hour before sex for six months. Participants were called for monthly visits for adherence assessment, product dispensing, risk-reduction counseling and condom dispensing (for pregnancy prevention as well as STI/RTI prevention). Participants were given an option of an off site study visit at their residence for these monthly procedures if they were unable to visit the study clinic. However, three monthly and six monthly visits were completed at the clinic to facilitate pelvic examination, colposcopy, HIV and RPR testing in addition to other visit procedures. During the pelvic examination at the three monthly visit, procedures identical to the enrollment visit were carried out. Urine samples were collected at enrollment and at the last follow up visit (after completing the product use for 6 months) and were tested for gonorrhoea and chlamydia infections by Polymerase Chain Reaction (PCR) using Roche Amplicor kits. At the enrollment visit and at each of the subsequent follow up visits, participants were provided with a user friendly pictorial diary page for adherence assessment with marking space for each day of a month to record when they actually used the tablet and or condom and or had sex. Each participant was followed up to six months.
Study end point:
The study endpoint was local toxicity as evidenced by ulceration, abrasion, severe erythema or edema determined by speculum assisted colposcopic examination, permanent product discontinuation or completion of product use for six consecutive months.
Grading of Laboratory Reports and Characterization of adverse events:
The National Institute of Allergy and Infectious Diseases Table for the Grading of Adult Adverse Experiences (AE) was used to exclude participants at the screening visit as per the inclusion criteria and characterize the severity of Adverse Events occurring during the study follow up visits (NIAID, unpublished document).
Results:
Between July 2004 and August 2005, 142 potentially eligible women were screened to enroll 100 participants in the study; 50 in the Praneem group and 50 in the placebo group. Enrollment was completed in September 2005 and the last participant completed the study in February 2006. Figure I provides the participant flow in the study. Baseline characteristics of the study participants are reported in Table I . The mean age of the study participants in the Praneem group was 30.4 years (range 21-40 years, SD 5.2 years) and that of in the placebo cohort was 30.5 years (range 22-45 years, SD 5.6 years).
Participant retention:
Of the 100 women enrolled, 49/50 (98%) participants from the Praneem group and 46/50 (92%) participants from the placebo group completed the 6 months study participation. Study discontinuation was not related to any adverse event. Participants in the Praneem group provided 303 person months of follow up and those in the placebo cohort provided with 298 person months with 6 scheduled follow up visits per participant after enrollment.
Sexual activity and reported product and condom use: Analysis of diary recordings indicated that in the Praneem group, the median number of reported tablets used, sex acts and condoms used per month were 9.7, 9.3 and 5.8 respectively. The corresponding figures in the placebo cohort were 10.7, 8.7 and 6.0. These differences were not statistically significant. (Table II) . Sixty per cent women of the women in the Praneem group and eighty three percent of the women from the placebo group reported product use in all the sex acts. Reported condom use was similar in all the enrolled women.
Adverse events:
Of the 159 adverse events reported (Table III) , 29 (18.2%) were unrelated to study product use as judged by the study clinician and 130 (81.8%) were possibly or probably related to study product use. In the placebo recipients, 74.1% events were related to product use compared to 89.7% in the Praneem group. This difference was statistically significant (p= 0.01). However, the severity of AEs was comparable in the Praneem and the placebo recipients.
Adverse events possibly related to product use noted during the 6-month study period: Table IV summarizes 130 adverse events reported during the 6-month study period by treatment group which are possibly or probably related to product use. Of these 130 events, 70 events were in the Praneem cohort as compared to 60 events in the placebo cohort. The overall incidence rate of events was 23.1 per 100 person-months of follow-up in the praneem group as compared to 20.1 in the placebo group. However, this difference was not statistically significant (p= 0.43).
The most commonly reported symptom was genital itching. Other incident clinical conditions or signs noted by the study clinician were primary herpes genitalis, secondary herpes genitalis, candidiasis, bacterial vaginosis, genital folliculitis, molluscum contagiosum, gonorrhoea, chlamydia and abrasion on the cervix possibly due to speculum trauma. There was no statistically significant difference in the incidence of these conditions in the two treatment groups. None of the participants reported any adverse event due to condom use.
There were no incident HIV infections in either of the cohorts. There were a total of 6 incident STIs (3 cases of primary genital herpes infection, 2 cases of recurrent genital herpes infection, 1 each of gonorrhoea) among the study participants with an incidence of 1.0 per 100 person months in this cohort (95% CI 0.37-2.17).
The mean vaginal pH values in the Praneem cohort at enrollment, 3 monthly follow up and at study exit were 4.4, 4.3 and 4.4 and the corresponding figures for the Placebo cohort were 4.3, 4.2 and 4.4.
Discussion:
Praneem polyherbal tablet has been reported to be safe for vaginal use in Phase I studies in HIV negative low risk women. This study evaluated expanded safety of Praneem polyherbal tablet in a randomized double-blind placebo controlled Phase II trial. No statistically significant differences were observed in the symptoms reported /events noted/ clinical signs or conditions noted among the participants enrolled in the Praneem group when compared to the placebo group. The most common symptom experienced by the product users was genital discomfort manifesting as genital itching, burning and pain. More events were reported in the Praneem group than in the placebo group, although the difference was not statistically significant. Genital epithelial disruptions are considered as one of the safety end points in microbicides trials because breaches in the genital epithelium are likely to increase the HIV transmission 22 and in this study these findings were rare with 2 events of abrasion possibly because of speculum trauma. The adverse events observed in the present study such as genital itching, burning, pain, IMB and burning micturation were similar to our earlier Phase I study using the same product 11 . The adverse experiences in our study are also consistent with the report of the Phase II study of Carraguard 23 . Reported product adherence and condom use was high in our study population and is consistent with previous report of Carraguard 23 . Participants who used other candidate microbicides products in other studies had also experienced similar symptoms in the same proportions 17, 18, 19 . There were no HIV seroconversions in this cohort. Although consistent condom use was very low at baseline, with risk reduction counseling and condom counseling at each of the follow up visits, reported condom use increased. Reported condom use was consistent among all the enrolled women. This high condom use might be responsible for the low incident STIs and no HIV seroconversion in this cohort.
To conclude, the long term safety of Praneem Polyherbal tablet appears promising however considering the failure of Nonoxynol-9 20 and Cellulose Sulphate in protecting women against HIV, a thorough preclinical assessment of the product following international guidelines which were published in 2004 21 after the present study was initiated needs to be done before this product is tested in Phase IIb/III studies. * The only severe adverse event reported was appendicectomy and was reported an event unrelated to study product use.
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Key message:
• Microbicides research is apriority worldwide.
• Praneem polyherbal tablet was safe for its long term use for 6 consecutive months when used by low risk women.
• Remaining pre-clinical evaluation as per the international guidelines should be taken up as a priority so as to move this product in further clinical trials
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